We’re thrilled to share that it was a great night for our Health team at this year’s Communique Awards Congratulations to everyone involved in the Severe Asthma Index with our clients Sanofi and Regeneron, a landmark study comparing end-to-end severe asthma strategy in 29 OECD countries. The Index won in the Best Use of Data Visualization and Excellence in Communication and Using Data categories, as well as being highly commended in the prestigious Progress Award in Healthcare and Scientific Communications.
Weber Shandwick’s Post
More Relevant Posts
-
What an incredible conversation about 'RWE for Informed and Impactful Decision Making'! At the International Congress on Rare Diseases and Orphan Drugs, we explored how real-world data (RWD) can transform healthcare, especially for rare diseases. A huge thank you to our expert panelists: Patrice Verpillat (EMA), who highlighted the groundbreaking DARWIN EU initiative, demonstrating the power of collaboration to harness RWD's potential. Niklas Hedberg (TLV), emphasizing that RWD has the potential to democratize drug development by making data access less exclusive. @Stanislav Kniazkov (WHO Europe), underscoring that building trust – through technical standards, effective regulation, transparency and collaboration – is crucial for RWD to be used confidently in global policymaking. Sergio Diaz (IQVIA), championing patient-led data collection and advocating for patient organizations to play a leading role in shaping RWD initiatives. We heard perspectives from regulators, HTA bodies, global health leaders, and patient advocates. While RWD complements traditional clinical data, we need rigorous technological frameworks, quality standards, and agreement on their implementation to ensure it fulfills its promise. My key takeaway: The future of healthcare decisions lies in the responsible, collaborative, and technically robust use of RWD. Thank you to the organizers and my dear friend Dimitrios Athanasiou MBA for having me as a moderator and for a thought-provoking discussion! RARE DISEASES GREECE European Medicines Agency WHO Regional Office for Europe IQVIA #RWE #RareDiseases #DARWINEU #HealthcareInnovation
To view or add a comment, sign in
-
🔍✨ Crafting a Compelling Value Proposition in #raredisease ✨🌐 With Rare Disease Day around the corner, the red thread | market access team has been pondering the unique aspects of crafting a value proposition in the rare disease / orphan drug space compared with general medicines. We thought it was a perfect moment to share our insights! Let's ease into it: In the world of rare, mixing precision and empathy isn't just about products - it's about leaving a meaningful mark on patients' lives - so what are the key ingredients for developing a compelling value proposition in rare disease? 1️⃣ Shift the narrative Instead of starting value talks in the early commercialisation phase, initiate these discussions earlier in the product lifecycle. By doing so, trials and HTA assessments can centre around your value proposition, giving it a solid foundation before commercial conversations begin. 2️⃣ Precision & Clarity Every word matters. Paint a clear picture of the unique value your solution brings, cutting through the complexity of rare diseases and support payers to understand what your brand offers. 3️⃣ Patient-Centricity Elevate the patient experience. Show how your offering addresses specific patient needs, this could be focused on the diagnostic odyssey, pathway and access challenges. 4️⃣ Collaboration & Advocacy Emphasise collaboration with the rare disease community. Highlight partnerships, support networks, and advocacy efforts. 5️⃣ Scientific Rigour In a space where every breakthrough is monumental, underscore the scientific foundation of your solution. Build trust through transparency. 6️⃣ Accessibility & Affordability Bridge the gap. Demonstrate a commitment to making your solution accessible and affordable, communicate the economic benefit but recognise the challenges within the rare disease ecosystem. How well does your value proposition align with its intended purpose and resonate with your target audience? 🤔 Reach out to Nick Leach or Victoria Thomas for an informal discussion on how to differentiate your value proposition in the rare disease space. #RareDiseaseDay #ValueProposition #PrecisionAndEmpathy
To view or add a comment, sign in
-
Following on with our “Think about Europe” campaign, today we are looking at some of the challenges with commercialising prevalent disease therapies in Europe, and why a pragmatic approach is so important. While the European market is large, problems arise when engaging with HTA bodies and payers which, if not managed carefully, can drive lower pricing than might be achieved in the US: ➡ Single and public payer healthcare systems, common in Europe, are highly sensitive to budget impact and will expect low pricing where expected volumes are high. ➡ Evidence requirements are higher in Europe and trials which are poorly aligned with European target country HTA guidelines will suffer pricing penalties. ➡ Most prevalent diseases have established drugs with strong supporting data gathered both through trials and real-world use. European drug pricing is anchored to these existing, often generic, therapies to avoid large leaps in budget impact. These are just a few of the hurdles manufacturers can face when commercialising prevalent disease therapies in Europe. Having explored many of these issues with clients, Cogentia’s team is well prepared to help you identify potential pitfalls for the European market and bring much needed treatments to patients with prevalent diseases across the region. At ISPOR US? Drop us a note or pass by stand #602. #MarketAccess #Europe #PrevalentDiseases #ISPORAnnual
To view or add a comment, sign in
-
Happy Rare Disease Day! I have closely witnessed the Rare Disease landscape develop over the past decade and have had the opportunity to work with clients making such life-changing products for rare disease patients. I would like to use this occasion to share some insights into some lessons we have learned working on numerous rare disease strategy and launch projects. 🌟Elevate Your Impact in Rare Disease Launches! 🌟 🚀 Supercharge Your Rare Disease Launch with Advanced Insights! Syneos has a wide range of rare disease and launch excellence offerings to support companies launching assets in rare diseases. Our latest offering aims specifically on building a holistic market understanding, measuring brand performance, and identifying areas of growth for the brand. 🌐 The Challenge: Rare disease launches demand a profound disease understanding, seamless health ecosystem connection, and a genuine grasp of the patient journey. Rise above the obstacles with our expertise! 💡 Our Solution: Our latest offering, Advanced Insights - where market intelligence meets strategy, empowers organizations to gain deep insights, enabling them to tailor their brand planning and launch strategies for more effective product launches in the rare disease space. 📈 Success Stories: Syneos helped a biopharmaceutical client understand disease area and treatment dynamics, measure brand performance, and identify areas of opportunity to inform their brand strategy and tactics in a rare disease indication. 🔗 #PharmaceuticalConsulting #RareDisease #MarketResearch #Innovation #syneoshealth
To view or add a comment, sign in
-
It’s happening soon—are you registered for our 2023 Microbiome Keynotes Symposium in Hollywood, FL, next month? At this October 20-22, 2023 event, you’ll learn how Pioneering the Microbiome translates into mapping the “axis” connections between the gut microbial community and other body-wide organs and structures. These gut-organ axis connections are complex and bidirectional interactive networks bridging the gut’s microbial community, its metabolites and by-products, and the organs/structures of the body.** We have a great lineup of experts and key thought leaders who’ll enrich your microbiome science expertise for use in clinical practice. You’ll learn to customize regimens, interpret clinical findings, and troubleshoot complex patient health concerns. Please REGISTER NOW here: https://lnkd.in/gQtMkQBx #PioneeringtheMicrobiome #2023AnnualMicrobiomeKeynotesSymposium #microbiome #microbiomehealth #guthealth #guthealthsupport #gutorganaxis #gutbodyaxis #YourParacticePartners #ScienceYouCanTrust **These statements have not yet been evaluated by the Food and Drug Administration (FDA). Products and claims are not intended to diagnose, treat, cure, or prevent any disease.
To view or add a comment, sign in
-
STOP THE PRESS…. We are delighted to be both speaking and exhibiting at this year’s World Orphan Drugs Congress. 𝗪𝗵𝗲𝗿𝗲 𝗰𝗮𝗻 𝘆𝗼𝘂 𝗳𝗶𝗻𝗱 𝘂𝘀? 📖 Come and meet us at stand S4. ☕ We don’t believe in the hard sell; our results speak for themselves. We're more of a let’s grab a coffee and see where we can help type of company. If you would like to know more, get in touch - info@redthreadmarketaccess.com 𝗪𝗵𝗮𝘁 𝗮𝗿𝗲 𝘄𝗲 𝘀𝗽𝗲𝗮𝗸𝗶𝗻𝗴 𝗮𝗯𝗼𝘂𝘁? Our very own Head of Strategic Market Access, Victoria Thomas will be discussing the critical steps involved in the development of compelling value propositions in rare diseases. Touching on topics such as: 💊 When is the right time to begin value related discussions? 💊 Given the complex and heterogenous nature of rare disease, how do you develop an authentic story which showcases value? 💊 How the patient voice can tear down barriers in rare disease and support value proposition development 💊 The use of RWE in rare diseases ❓ Would you like a copy of Victoria's presentation? Let us know in the comments or drop us a note. #marketaccess #valueproposition #rarediseases #rarediseaseawareness #raredisease
To view or add a comment, sign in
-
Did you miss our latest webinar? No problem - we've curated an extensive library of over 20 market access webinar recordings, available upon request for you to watch in your own time💡 Our commitment is to share valuable resources for your market access journey and help your team to be on the cutting edge of developments in the market access landscape. Check out some of the engaging topics we've covered recently: - Navigating EU HTA – the future of supranational HTA initiatives; lessons learnt so far… - The value of Delphi panels in accelerating patient access - Breaking down barriers to access in Europe - getting it right first time for rare diseases! Explore the full range of market access webinars, exclusively available for biopharma companies, and request recordings here: https://lnkd.in/exewTNnb #MarketAccess #PatientAccess #Webinars
To view or add a comment, sign in
-
This Rare Disease Day (29th February), we are hosting an exciting webinar, which will explore some of the opportunities and challenges of launching orphan medicines in secondary markets. I will be presenting my research into the market access conditions in the MENA regions, with a focus on the rare disease reimbursement landscape in growth markets in Egypt, Saudi Arabia, and the United Arab Emirates. We will contrast this with Michelle James' (Associate Consultant – Global Market Access) research into the market access and reimbursement routes in the more established, yet smaller populations in the Nordic regions, specifically Denmark, Sweden, and Norway. We will explore these contrasting regions to showcase the significant differences between markets when it comes to: ➡️ Overall and rare disease patient populations ➡️ Access inequalities ➡️ Time to diagnosis ➡️ Access to innovation timelines ➡️ Healthcare funding ➡️ Health technology assessment frameworks Clare Foy (Director – Global Market Access) will then lead a discussion about the opportunities and challenges of launching in markets with different conditions and requirements, and how this should play into your overarching Global market access strategy. Learn more about this webinar at https://lnkd.in/eGV6Wm-M If you can't make the date, please register and we'll send you a link to the recording shortly after the webinar: https://lnkd.in/e5CiqQRy #raredisease #marketaccess #orphanmedicine #orphandrugs #Pharma #Nordic #MENA #rarediseaseday
To view or add a comment, sign in
-
📢 As we forge ahead, it is crucial to remember that each partner in this journey brings unique strengths. By working in concert, we can strive towards a future where all people living with a #RareDisease have #access to effective #treatment and the hope for a better quality of life. Read the op-ed our Secretary General, Alexander Natz, wrote for the Rare Disease supplement for The Parliament. Alexander urges a holistic and realistic approach to #OMP reform and action. Such approach must integrate diverse policy solutions under a unified vision through the product lifecycle and should be partnership-driven to transform the landscape of rare disease treatments and #research across #Europe. 👉 https://lnkd.in/dCf3TmNt #RDD2024 #RareDiseaseWeek #OrphanDrugs #Innovation #PatientAccess Takeda EURORDIS-Rare Diseases Europe
A holistic, realistic approach to OMP reform and action
theparliamentmagazine.eu
To view or add a comment, sign in
-
https://lnkd.in/g9Xgbp-6 Big step in developing new medicine to prevent and control AMR by Important Stakeholders engagement
Access to Novel Medicines Platform: Meeting of Working Group 4 on novel antimicrobials
who.int
To view or add a comment, sign in
398,906 followers